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Abstract 
 
Aortic augmentation index (AIx) is a marker of central aortic pressure burden and is 
modulated by antihypertensive drugs. In patients with peripheral arterial disease 
(PAD) and antihypertensive treatment aortic pressures parameters, the heart rate 
adjusted augmentation index (AIx75) and the unadjusted AIx were determined.  
The (aortic) systolic and diastolic blood pressure did not differ between PAD patients 
with beta blockers (n=61) and without beta blockers (n=80). In patients with beta 
blockers, augmentation pressure and pulse pressure were higher than in patients 
without beta blockers (augmentation pressure p=0.02, pulse pressure p=0.005). 
AIx75 was lower in PAD patients with beta blockers than in patients without beta 
blockers (p=0.04), while the AIx did not differ between PAD patients with and without 
beta blockers. In summary, the present study demonstrates that beta blockers 
potentially affect markers of vascular hemodynamics in patients with PAD. Because 
these markers are surrogates of cardiovascular risk, further studies are warranted to 
clarify the impact of selective beta blocker treatment on clinical outcome in patients 
with PAD.  
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1. Introduction 
 
Peripheral arterial disease (PAD) is a common manifestation of advanced 
atherosclerosis. In industrialized countries PAD affects almost one fourth of the 
population over the age of 50 [1]. PAD is associated with a substantial increase in 
cardiovascular morbidity and mortality compared to healthy subjects [2]. Therefore, 
cardiovascular risk reduction is the primary goal in the therapeutic management of 
PAD patients. 
In patients with clinically manifest atherosclerosis the central augmentation index 
(AIx) has emerged as independent predictor for the future occurrence of 
cardiovascular events [3]. The Aix constitutes the proportion between the second and 
first peak of the arterial pulse wave. It can be measured non-invasively by radial 
applantation tonometry. The AIx mainly depends on pressure wave reflections from 
peripheral arteries and peripheral arterial stiffness. 
Peripheral arterial tone as well as wave reflections may potentially be influenced by 
antihypertensive medication. Previous data have shown that antihypertensive drugs 
can differently influence the arterial pulse wave morphology and the AIx [4]. Within 
the spectrum of antihypertensive drugs beta blockers are related to a higher AIx as 
consequence of their negative chronotropic properties [4]. In patients with PAD 
angiotensin-converting enzyme inhibitors (ACE-I) have been proposed to lower the 
AIx [5]. Whilst ACE-I have been well established as antihypertensive treatment in 
patients with PAD the use of beta blockers is controversially debated over the past 
years [6-8]. 
Up to now, there is no evidence that beta blockers adversely affect the peripheral 
arterial perfusion and PAD associated symptoms [9]. In particular, the impact of beta 
blockers on vascular hemodynamics in patients with PAD is still matter of discussion.  
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Hence, the aim of the present study was to assess differences in vascular 
hemodynamics between PAD patients with and without beta blocking treatment in the 
setting of a cross-sectional study. 
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2. Methods 
 
2.1. Patients 
Consecutive patients with stable PAD (Rutherford categories 0-3) who were referred 
to the Clinic of Angiology at the University Hospital Zurich were eligible for this study. 
Exclusion criteria comprised critical limb ischemia (Rutherford categories 4-6), the 
presence of an inflammatory vascular disease as well as cardiac arrhythmias.  
The study was performed according to the recommendations of the Declaration of 
Helsinki and the ICH-GCP guidelines and the protocol was approved by the 
institutional ethical committee. Before inclusion written informed consent was 
obtained in all patients. 
 
2.2. Clinical data 
All patients underwent a complete clinical examination. Demographic data including 
patients’ age, sex, body mass index (BMI), smoking habits as well as each patients’ 
medication were systematically recorded. The diagnosis of PAD was established 
according to current guidelines [10]. Patients with PAD were clinically classified 
according to Rutherford’s categories for PAD [11]. 
The presence of arterial hypertension and dyslipidemia were diagnosed referring to 
the respective guidelines [12, 13]. Diabetes mellitus was diagnosed in patients on 
continuous antidiabetic medication or in accordance with current recommendations 
for the diagnosis of diabetes [14]. The presence of coronary artery disease or 
cerebrovascular disease was declared upon the patients’ medical history. Besides 
arterial hypertension, a history of coronary artery disease was an indication for the 
use of beta blockers and/or ACE-I/ARB. 
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2.3. Generation/class of beta blockers 
For further differentiation beta blockers were stratified by generation [15]: first 
generation/nonselective beta blockers: propranolol; second generation/selective β1 
blockers: atenolol, metoprolol, bisoprolol, third generation/beta blockers with 
assumed vasodilating activity: carvedilol, nebivolol. 
 
2.4. Hemodynamic measurements 
Blood pressure and pulse wave analyses were performed in a quiet room with a 
constant room temperature after a resting period of 15 minutes. All measurements 
were obtained in a supine patient position. 
As previously published, blood pressure measurements of the lower limbs were 
obtained using a hand-held 6-MHz Doppler probe (Kranzbühler, Logidop 2, Pilger 
Medical Electronics, Switzerland) and appropriate sphygmomanometer cuffs [16]. 
Thereby, the systolic blood pressures of the anterior and posterior tibial arteries were 
measured at the ankle of each patient’s limb. Further, bilateral brachial blood 
pressure measurements were obtained in all patients. The ankle brachial index (ABI) 
for each leg was calculated as the ratio of the highest systolic ankle blood pressure 
of the respective side and the highest systolic brachial blood pressure of both sides. 
For further analyses the ABI of the most affected limb was used. Radial artery 
pressure waveforms were recorded by applanation tonometry using a high-fidelity 
micromanometer (Millar Instruments, Houston, TX, USA) [17]. The aortic pressure 
waveforms were derived from the radial pressure waveforms using the SphygmoCor 
software (AtCor Medical; Sydney Australia) and a generalized transfer function [18]. 
The (aortic) systolic blood pressure and the (aortic) diastolic blood pressure were 
determined from the aortic pressure waveforms. The (aortic) pulse pressure was 
calculated as difference between the systolic blood pressure and the diastolic blood 
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pressure. The (aortic) augmentation pressure constitutes the differences between the 
second and first peaks of the central (aortic) pressure waveform. The AIx [%] was 
calculated as ratio between the augmentation pressure and the pulse pressure. As 
main outcome parameter the AIx was adjusted to a heart rate of 75 bpm (AIx75). In 
addition, the unadjusted AIx was analyzed. 
 
2.5. Statistical analysis 
Continuous data are presented as mean ± standard deviation. Discrete data are 
given as counts and percentages. The primary endpoint was the difference in 
hemodynamic variables (AIx75, AIx, PP, augmentation pressure, aSBP, aDBP) 
between users and nonusers of the respective antihypertensive drugs (ACE-I, BB, 
CCB and diuretics). For study analyses ACE-I and angiotensin receptor blockers 
(ARB) were grouped as one class of antihypertensive drugs. For group comparisons 
an independent-samples t-test was run. Correlations were examined by calculating 
Pearson or Spearman-Rho correlations coefficients as appropriate. Multivariate linear 
regression analysis was used to further assess the independent association between 
bb intake and Aix75. A two-sided p-value <0.05 was considered statistically 
significant. Calculations were performed using SPSS for Mac (Version 20.0, SPSS 
Inc Chic., IL, USA). 
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3. Results 
 
In total 141 patients with a mean age of 68.9 ± 10.5 years (90 males, 63.8 %) who 
were admitted to the Clinic of Angiology at the University Hospital Zurich were 
included into this cross sectional study. Of these 141 patients 45 patients (31.9%) 
were classified as Rutherford category 0, 33 patients (23.4%) were classified as 
Rutherford category 1 or 2 and 63 patients (44.7%) as Rutherford category 3. 
Included patients had a mean BMI of 25.5 ± 4 kg/m2, 91 (64.5%) patients were 
diagnosed with dyslipidemia and 37 (26.2%) patients with type 2 diabetes mellitus. A 
history of arterial hypertension was present in 116 patients (82.3%), a history of 
coronary artery disease in 41 patients (29.1%). 
Of the included 141 patients, 61 patients (43.3%) were on beta blockers (beta 
blockers of the first generation: 2 patients, beta blockers of the second generation: 49 
patients, beta blockers of the third generation: 10 patients). Demographic and clinical 
data of patients, who were on beta blocker treatment, and patients without beta 
blockers are given in Table 1. 
 
3.1. Antihypertensive drugs and vascular hemodynamics 
The AIx75 was lower in patients on beta blockers than in patients not taking beta 
blockers (p=0.04, Figure 1A), while the (heart rate unadjusted) AIx did not differ 
between patients with and without beta blockers (Figure 1B). Heart rate (69 ± 10 
bpm) was inversely related to the (heart rate unadjusted) AIx (p=-0.42, r<0.0001). In 
PAD patients the AIx75 was lower than the AIx (AIx75: 30.9 ± 7.8% vs. AIx: 33.7 ± 
8.4%, p<0.0001). The difference between AIx75 and AIx was more pronounced in 
patients with beta blockers than in patients without beta blocker treatment (Figure 2). 
The generation of beta blockers was neither associated with the AIx75 (p=0.47, 
Spearman correlation coefficient r=0.1), nor with the (heart rate unadjusted) AIx 
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(p=0.94, Spearman correlation coefficient r=0.01). Further, the ABI (of the mainly 
affected limb) was neither related to the AIx75 (p=0.11, Pearson correlation 
coefficient r=-0.14), nor to the (unadjusted) AIx (p=0.23, Pearson correlation 
coefficient r=-0.16). The pulse pressure and the augmentation pressure were higher 
in patients taking beta blockers than in patients without beta blockers (Table 2).  
No significant difference in AIx75 and unadjusted AIx was found between patients 
who were on ACE-I/ARB, CCB and diuretics in comparison with patients without the 
respective antihypertensive drugs (Figure 1A+B). Patients who received ACE-I/ARB 
had higher systolic blood pressure values than patients who were not on that 
medication (Figure 3A). No differences of diastolic blood pressure values were 
observed between users and non-users of ACE-I/ARB, beta blockers, CCB and 
diuretics (Figure 3B). 
 
3.2. Multivariate model 
To account for potential confounders we included patients’ age, sex, heights, 
smoking status, pulse pressure and use of other antihypertensive drugs (e.g. ACE-
I/ARB, CCB, diuretics) in a multivariate model. In this model, beta blocker-treatment 
was still related to a significantly lower AIx75 (mean adjusted difference: -4.1; 95% CI 
-7.9, -0.3; p=0.04). In contrast ACE-I/ARB, CCB and diuretics were not related to the 
AIx75 in this model (ACE-I/ARB: mean adjusted difference 0.1; 95% CI -3.6, 3.9; 
p=0.94, CCB: mean adjusted difference -3.3; 95% CI -7.4, 0.8; p=0.11, diuretics: 
mean adjusted difference 0.3; 95% CI -3.3, 4; p=0.85). 
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4. Discussion 
The main finding of the present study is that PAD patients taking beta blockers had a 
lower AIx75 compared to patients without beta blockers. Comparable differences 
were not found for the other main classes of antihypertensive drugs (ACE-I/ARB, 
CCB and diuretics). 
In the therapeutic management of PAD adequate blood pressure control is an 
important aim. According to the reduction of cardiovascular events in the Heart 
Outcomes Prevention Evaluation (HOPE) study ACE-I have been established as 
preferred antihypertensive drug in PAD patients [6]. In the past, in PAD patients 
(early generation) beta blockers were avoided as antihypertensive drugs according to 
an allegedly unfavorable effect on peripheral perfusion [8]. However, concerns on the 
use of beta blockers in PAD were refuted by a meta-analysis with 11 randomized 
controlled studies, which showed that beta blockers did not adversely affect 
symptoms in patients, with mild to moderate peripheral perfusion deficits [19]. 
Regarding vascular hemodynamics another, more recent meta-analysis 
demonstrated an association between beta blockers and an increase in AIx in 
hypertensive patients [20]. It should be noted, however, that neither of these studies 
allows conclusions to be drawn with respect to the relation between beta blockers 
and the AIx in PAD patients.  
Focusing on PAD patients the present study revealed a lower AIx75 in subjects 
receiving beta blockers than in those not taking them. In line with previous data, the 
AIx was inversely related to the heart rate in the present study [21]. Although the 
heart rate was lower in patients with beta blockers than in patients without beta 
blockers, the unadjusted AIx did not differ between both groups. It has to be noted, 
however, that adjustment for heart rate led to a decrease in AIx in patients with and 
without beta blockers. This might conjointly be attributed to the average heart rate, 
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which was below 75 bpm in the majority of included patients, as well as to the inverse 
correlation between heart rate and the AIx. In analogy to these associations the 
decline from AIx to AIx75 was more pronounced in patients with beta blockers (with a 
larger heart rate difference between baseline and the adjusted heart rate of 75 bpm) 
than in patients without beta blockers. 
Interestingly, neither the ABI nor the generation of beta blocker was associated with 
the AIx75 in PAD patients. The comparably lower AIx75 in PAD patients with beta 
blockers stands in contrast to previous findings on the AIx in hypertensive patients 
[20]. Apart from the above mentioned impact of heart rate on the difference in AIx 
between patients with and without beta blockers two mechanisms could additionally 
contribute to beta blocker-associated differences of the AIx75: beta blocker affect the 
cardiac inotropy, which might consequently have an impact on the AIx75. Secondly, 
beta blocker might target the magnitude of peripheral pulse wave reflections. 
Notably, the AIx75 is not a measure, but constitutes a ratio between the 
augmentation pressure and the pulse pressure. In the present study both 
components, the augmentation pressure and the pulse pressure, were higher in PAD 
patients taking beta blockers than in patients without beta blockers.  
The pulse pressure itself constitutes the difference between the systolic and diastolic 
blood pressure. In the present study, the systolic blood pressure tended to be higher 
and the diastolic blood pressure tended to be lower in patients with beta blockers 
than in patients without beta blockers. Taken separately, the between-group 
differences in systolic and diastolic blood pressure were statistically not significant. 
However, these differences seem to sum up in the pulse pressure, which 
subsequently explains the higher pulse pressure in PAD patients with beta blockers 
than in patients without beta blockers. 
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Regarding other antihypertensive drugs, systolic blood pressure was higher in PAD 
patients with ACE-I than in PAD patients without ACE-I. Nevertheless, we found no 
significant difference in AIx between patients with and without ACE-I treatment. In 
purely arithmetical terms, this is a consequence of not only higher systolic blood 
pressure, but also higher diastolic blood pressure in patients with ACE-I of the 
present study.  
The second component of the AIx75, the augmentation pressure, is a surrogate of 
wave reflection [22]. In the present study the augmentation pressure was higher in 
PAD patients with beta blockers than in those without beta blockers. However, the 
difference in augmentation pressure between patients with and without beta blockers 
was much less pronounced than the difference in pulse pressure. Accordingly, the 
ratio of both components – with the pulse pressure as denominator – led to the lower 
AIx75 in PAD patients with beta blockers. 
The findings of the present study have to be viewed in the light of its limitations: first, 
the modest sample size of the present study has to be acknowledged. Although we 
detected significant differences in AIx75 between patients with and without beta 
blockers, we cannot exclude that a larger number of patients would have revealed 
further differences of other blood pressure lowering drugs. Secondly, this study is a 
cross-sectional study without follow-up measurements of the AIx75. Therefore, the 
proposed findings have to be interpreted with caution regarding a potential causal 
connection between the intake of beta blockers and the AIx75. 
Nonetheless, the major strength of this investigation warrants mention: up to now, 
data on the impact of beta blockers on vascular hemodynamics in patients with PAD 
are scarce. To our knowledge, this is the first investigation showing a potential impact 
of beta blockers on vascular hemodynamics in patients with PAD. Nevertheless, 
further studies are required to clarify, whether the lower AIx75 and higher pulse and 
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augmentation pressures in PAD patients on beta blockers has an impact on clinical 
outcome. 
 
Conclusion 
In PAD, central aortic hemodynamics may be affected by beta blocker treatment. 
Additional studies are needed to clarify whether the association between beta 
blockers and vascular hemodynamics contributes to clinical outcome in PAD. 
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Figure legends 
 
Figure 1 
 
Bar charts (means) and respective error bars (± 2SE) illustrating the (A) heart rate 
adjusted (75 bpm) aortic augmentation index (AIx75), (B) the unadjusted aortic 
augmentation index (AIx) in patients with peripheral arterial disease receiving/not 
receiving angiotensin-converting enzyme inhibitors (ACE-I)/angiotensin receptor 
blockers (ARB), beta blockers, calcium channel blockers (CCB) and/or diuretics. 
 
Figure 2 
 
Bar charts (means) and respective error bars (± 2SE) illustrating the unadjusted 
augmentation index (AIx) vs. the heart rate adjusted augmentation index (AIx75) in 
patients with peripheral arterial disease receiving/not receiving beta blockers. 
 
Figure 3 
 
Bar charts (means) and respective error bars (± 2SE) illustrating the (A) aortic 
systolic blood pressure, (B) aortic diastolic blood pressure in patients with peripheral 
arterial disease receiving/not receiving angiotensin-converting enzyme inhibitors 
(ACE-I)/angiotensin receptor blockers (ARB), beta blockers, calcium channel 
blockers (CCB) and/or diuretics. 
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19 
Figure 3. 
 
 
 
